Clinical trials: Interdigitating Dendritic Cell Sarcoma
Leukemia, Lymphoma
Immunotoxin in Treating Patients With Leukemia or Lymphoma
RATIONALE: Immunotoxins can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00002765
- Testing
- LMB-2 immunotoxin
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Cancer
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Indinavir and ritonavir may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00637637
- Testing
- indinavir sulfate, ritonavir, radiation therapy
- Where
- 3 sites in Switzerland
- Volunteers
- 60 people
- Sponsor
- Oncology Institute of Southern Switzerland
Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma
Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
This phase I trial is studying the side effects and best dose of gossypol when given together with paclitaxel and carboplatin in treating patients with solid tumors that are metastatic or cannot be removed by surgery.
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT00891072
- Testing
- R-(-)-gossypol acetic acid, paclitaxel, carboplatin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Peripheral T Cell Lymphoma Unspecified, Anaplastic Large Cell Lymphoma, ALK-negative
RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas
The urgent need for new effective therapy for T-cell lymphoma patients and promising results observed so far in trials with RAD001(everolimus, mTOR inhibitor) strongly warrants the investigation of RAD001 combined with CHOP as a…
- Conditions
- Peripheral T Cell Lymphoma Unspecified, Anaplastic Large Cell Lymphoma, ALK-negative, Angioimmunoblastic T Cell Lymphoma, Cutaneous T Cell Lymphoma
- Trial name
- RADCHOP (NCT01198665)
- Testing
- RAD001 (Everolimus)
- Where
- 5 sites in South Korea
- Volunteers
- 46 people
- Sponsor
- Samsung Medical Center
Graft Versus Host Disease, Leukemia
Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
RATIONALE: A donor peripheral stem cell transplant helps stop the growth of cancer cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood…
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00725062
- Testing
- CD4+CD25+ regulatory T cells, allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Diffuse Large Cell Lymphoma Relapsed/Refractory
Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
The goal of this clinical trial is to show that incorporating ofatumumab instead of rituximab in combination with etoposide and cytarabine (OVA) is successful in collecting autologous stem cells for use in an autologous stem cell…
- Trial name
- NCT01555541
- Testing
- Ofatumumab, Etoposide, Cytarabine
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- C. Babis Andreadis
Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma
Study of Pembrolizumab (MK-3475) in Combination With Romidepsin
This phase I/II trial studies the side effects of pembrolizumab and romidepsin and to see how well they work in treating participants with peripheral T-cell lymphoma that has come back or that does not respond to treatment.
- Conditions
- Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides
- Trial name
- NCT03278782
- Testing
- Pembrolizumab, Romidepsin
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma
RATIONALE: MP470 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This clinical trial is studying the side effects and best dose of MP470 in treating patients with unresectable…
- Trial name
- NCT00504205
- Testing
- multitargeted receptor tyrosine kinase inhibitor MP470, laboratory biomarker analysis, pharmacological study
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Astex Pharmaceuticals, Inc.
DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL
The goal of this clinical trial is to evaluate clinical efficacy of incorporating Epcoritamab into the salvage treatment routine for relapsed-refractory aggressive B-cell lymphoma, followed by autologous stem-cell transplantation…
- Conditions
- DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, DLBCL, Nos Genetic Subtypes
- Trial name
- NCT06287398
- Testing
- Epcoritamab
- Where
- Australia
- Volunteers
- 39 people
- Sponsor
- Australasian Leukaemia and Lymphoma Group
Chronic Myeloproliferative Disorders, Leukemia
Caregiver Support in the Coping of Patients Who Are Undergoing a Donor Bone Marrow Transplant
RATIONALE: Questionnaires that measure coping may improve the ability to plan supportive care for patients undergoing donor bone marrow transplant.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00281814
- Testing
- psychosocial assessment and care
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- The Cleveland Clinic
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma
This phase I/II trial studies the side effects and best dose of panobinostat and everolimus when given together and to see how well they work in treating patients with multiple myeloma, non-Hodgkin lymphoma, or Hodgkin lymphoma…
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, B-cell Adult Acute Lymphoblastic Leukemia
- Trial name
- NCT00918333
- Testing
- panobinostat, everolimus, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 124 people
- Sponsor
- Mayo Clinic
Chidamide, R-CHOP Chemotherapy
Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes
Evaluation of the Safety and Efficacy of CR-CHOP Treatment in Newly Diagnosed Double-Expressor DLBCL with Other Molecular Subtypes
- Conditions
- Chidamide, R-CHOP Chemotherapy, DLBCL - Diffuse Large B Cell Lymphoma, Double-expressor Lymphoma (DEL)
- Trial name
- NCT06891157
- Testing
- Chidamide plus R-CHOP
- Where
- China
- Volunteers
- 148 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
AIDS-related Lymphoma, Adult Non-Hodgkin's Lymphoma
Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy, such as etoposide, methylprednisolone, cytarabine, and cisplatin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- AIDS-related Lymphoma, Adult Non-Hodgkin's Lymphoma, Anaplastic Large Cell Lymphoma
- Trial name
- NCT00310128
- Testing
- cisplatin, cytarabine, etoposide
- Sponsor
- AIDS Malignancy Consortium
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer. PURPOSE: Phase I trial to study the effectiveness of VEGF Trap in treating patients who have relapsed or…
- Trial name
- NCT00045266
- Testing
- ziv-aflibercept
- Where
- United States
- Sponsor
- Regeneron Pharmaceuticals
Chronic Myeloproliferative Disorders, Leukemia
Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill metastatic cancer cells. Interferon alfa may interfere with the growth of the cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00002504
- Testing
- aldesleukin, recombinant interferon alfa
- Where
- 5 sites in United States
- Sponsor
- Hoag Memorial Hospital Presbyterian
Lymphoma
S0501 Fludarabine, Melphalan, and Donor Stem Cell Transplant Followed By Tacrolimus and Methotrexate in Treating Patients for Relapsed Lymphoma
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and melphalan, before a donor bone marrow or peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Trial name
- NCT00121186
- Testing
- fludarabine phosphate, melphalan, methotrexate
- Where
- 33 sites in United States
- Volunteers
- 1 people
- Sponsor
- SWOG Cancer Research Network
Lymphoma
Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00244985
- Testing
- rituximab, pegylated liposomal doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Roswell Park Cancer Institute
Leukemia, Lymphoma
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and busulfan, before a donor bone marrow or peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma, Plasma Cell Neoplasm
- Trial name
- NCT00053196
- Testing
- anti-thymocyte globulin, G-CSF, busulfan
- Where
- 12 sites in United States
- Volunteers
- 82 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Lymphoma
Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Giving high doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells.
- Trial name
- NCT00521261
- Testing
- anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Lymphoma
Molecular Risk Assessment in Planning Treatment for Patients With Non-Hodgkin's Lymphoma
RATIONALE: Analyzing genes that are present in cancer cells may be useful as a method for predicting the response of non-Hodgkin's lymphoma to cancer treatment.
- Trial name
- NCT00055640
- Testing
- rituximab, cyclophosphamide, doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Case Comprehensive Cancer Center